A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.

Jovanović B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, Grau AM, Lehmann BD, Shyr Y, Sheng Q, Chen SC, Arteaga CL, Pietenpol JA
Clin Cancer Res. 2017 23 (15): 4035-4045

PMID: 28270498 · PMCID: PMC5540799 · DOI:10.1158/1078-0432.CCR-16-3055

MeSH Terms (17)

Adult Cisplatin DNA Damage Drug-Related Side Effects and Adverse Reactions Everolimus Female High-Throughput Nucleotide Sequencing Humans Ki-67 Antigen Lymphocytes, Tumor-Infiltrating Middle Aged Mutation Neoplasm Staging Paclitaxel Receptors, Androgen Treatment Outcome Triple Negative Breast Neoplasms

Connections (3)

This publication is referenced by other Labnodes entities:

Links